Astrotech Corporation (NASDAQ: ASTC) — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended December 31, 2023 (Astrotech fiscal 2024 second quarter), not 2022 Q2 as stated in the request metadata. Financial amounts below are in millions of dollars unless noted.
Business context and reporting period
Astrotech commercializes mass-spectrometry technology through subsidiaries focused on security detection (1st Detect), agriculture and distillation process control (AgLAB), breath analysis (BreathTech), and chemical manufacturing process control (Pro-Control). The quarter’s reported revenue was primarily from TRACER 1000 sales, consumables, and maintenance services. The statements are unaudited.
Financial performance and liquidity
| Metric | Three months ended Dec. 31, 2023 | Three months ended Dec. 31, 2022 | Six months ended Dec. 31, 2023 | Six months ended Dec. 31, 2022 |
|---|---|---|---|---|
| Revenue | $1.115 | $0.263 | $1.540 | $0.301 |
| Gross profit / margin | $0.532 / 48% | $0.108 / 41% | $0.715 / 46% | $0.114 / 38% |
| Operating expenses | $3.600 | $2.922 | $7.118 | $5.692 |
| Operating loss | $(3.068) | $(2.814) | $(6.403) | $(5.578) |
| Net loss | $(2.641) | $(2.418) | $(5.553) | $(4.947) |
| Net loss per share | $(1.62) | $(1.50) | $(3.40) | $(3.07) |
- For the six months, operating cash outflow was $4.850 million, compared with $4.255 million in the prior-year period. Investing activities provided $1.828 million, primarily reflecting investment proceeds; financing activities used $0.090 million. Cash and cash equivalents fell $3.112 million to $11.096 million.
- At December 31, cash plus short-term investments totaled $37.279 million ($11.096 million cash and $26.183 million investments). Working capital was approximately $37.8 million. Total assets were $42.831 million and stockholders’ equity was $40.274 million.
- Total liabilities were $2.557 million. The balance sheet reports no outstanding related-party borrowing; lease liabilities totaled $0.461 million. The prior related-party note was repaid in 2022.
Material changes versus the prior comparable period
- Quarterly revenue increased $0.852 million, chiefly from delivery of previously announced TRACER 1000 orders. The company said seven units for an airport checkpoint in Romania were delivered during the quarter; an earlier 14-unit order had also been fulfilled.
- Six-month revenue rose $1.239 million. Gross margin improved by 8 percentage points year over year, which management attributed to design improvements reducing warranty expense and a higher comparative sales price.
- Quarterly operating expenses rose 23.2%; six-month expenses rose 25%. Higher SG&A reflected sales-related and legal expenses; higher R&D reflected staffing, cross-platform development, and subsidiary product and method development.
- Despite substantially higher sales, operating and net losses increased. Higher interest income on short-term investments partly offset operating losses.
- Operating cash use increased by $0.595 million year over year. Cash and short-term investments together declined from $42.127 million at June 30, 2023 to $37.279 million at December 31, 2023.
Outlook, management commentary, risks, and unusual items
- The filing provides no specific revenue, earnings, or cash-flow guidance. Management said there had been no material update to its short- and long-term liquidity and operating-capital expectations since the fiscal 2023 Form 10-K.
- TRACER 1000 has been deployed at approximately 29 locations in 14 countries. U.S. TSA cargo detection and non-detection testing resumed after the quarter; detection testing is a step toward possible placement on the approved list. Approval and subsequent field trials are not assured.
- AgLAB and Pro-Control remain commercialization opportunities, while BreathTech is developing its BreathTest-1000 with a Cleveland Clinic study. Management cited field-trial results for AgLAB, including average yield improvement claims of approximately 30% and a later 32% revenue-related claim; these are company-reported results, not guarantees of customer outcomes.
- Key risks include customer and revenue concentration (two customers comprised materially all revenue in the current period), uncertain product demand and market acceptance, TSA approval delays, supply-chain availability and cost inflation, competition, development execution, and evolving hemp/cannabis regulation. The company said it believes it can pass some input-cost increases to customers but warned prolonged shortages could harm results.
- All net deferred tax assets are covered by a valuation allowance; the company reported approximately $486,000 of uncertain tax positions and did not expect significant changes over the next 12 months. It reported no current litigation in the financial-statement notes and no material adverse effect expected from disclosed legal matters.
- The stockholder rights plan was extended to December 20, 2024. Management reported effective disclosure controls as of December 31, 2023 and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the period: this is the December 31, 2023 quarter, despite the request’s “2022 Q2” label.
- Review the source and sustainability of the TRACER 1000 order-driven revenue and the two-customer concentration.
- Track TSA cargo testing, any ACSTL approval, and subsequent field-trial progress; none is assured by the filing.
- Assess cash burn against the company’s $37.279 million of cash and short-term investments and its stated liquidity expectations.
- Validate AgLAB’s reported field-trial performance and the commercial progress of AgLAB, Pro-Control, and BreathTech.
- Consider operating losses, rising operating expenses, supply-chain and regulatory risks, and the extended rights plan.